Veru (NASDAQ:VERU) Stock Picked Up by Analysts at Westpark Capital

Equities researchers at Westpark Capital initiated coverage on shares of Veru (NASDAQ:VERU – Get Free Report) in a research note issued on Tuesday, Marketbeat.com reports. The firm set a “buy” rating on the stock.

Other equities analysts have also issued reports about the company. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Wall Street Zen lowered Veru from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Veru currently has an average rating of “Moderate Buy” and an average price target of $24.50.

Get Veru alerts:

Get Our Latest Report on Veru

Veru Stock Down 3.1%

Veru stock traded down $0.08 during midday trading on Tuesday, reaching $2.47. 1,517,504 shares of the stock traded hands, compared to its average volume of 736,582. The stock’s fifty day moving average is $2.53 and its 200-day moving average is $2.53. Veru has a 12 month low of $2.05 and a 12 month high of $7.33. The stock has a market cap of $42.11 million, a P/E ratio of -3.58 and a beta of -1.21.

Veru (NASDAQ:VERU – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02. On average, equities analysts predict that Veru will post -1.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Veru

Several institutional investors have recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in shares of Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after buying an additional 5,008 shares during the period. Renaissance Technologies LLC purchased a new position in Veru during the 1st quarter worth $153,000. Finally, FNY Investment Advisers LLC purchased a new position in Veru during the 2nd quarter worth $328,000. Institutional investors own 47.16% of the company’s stock.

About Veru

(Get Free Report)

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.

Read More

• Five stocks we like better than Veru
• Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
• Lamb Weston’s Turnaround Is Starting to Look Real
• These 3 Stocks Got the Most Love From Analysts in September
• Record French Debt Could Create Opportunities for U.S. Market Operators

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.